Sch. of Med., C h i l d r e n s H o s p i t a l o f Los Angeles, Dept. of Peds., Los Angeles.
A 6 y r o l d g i r l ( P t l ) p r e s e n t e d w i t h p u b i c h a i r , a c n e and body odor f o r 1 y r . Ht was a t t h e 95th c e n t i l e and bone age (BA) was 8 y r s ; s h e had s t a g e I1 p u b i c h a i r , a c n e and mild c l i t o r o m e ga l y . Serum 17-hydroxyprogesterone (17-OHP), a n d r o s t e n e d i o n e , and t e s t o s t e r o n e (T) were 218, 46 and 40 n g / d l ; LH, FSH and E2 were p r e p u b e r t a l . Her s i s t e r ( P t 2 ) was asymptomatic a t 2 t y r s ; a t 33 y r s h e r h t had i n c r e a s e d from t h e 7 5 t h t o t h e 9 0 t h c e n t i l e and h e r BA was 4 t y r s . She had o c c a s i o n a l a c n e and body odor. T h e i r 9 y r o l d b r o t h e r ( P t 3 ) was a t t h e 5 0 t h c e n t i l e f o r h t w i t h a BA of 9 y r s and no s i g n s of v i r i l i z a t i o n . The mother ( P t 4 ) was 162cm t a l l , obese and h i r s u t e ; s h e had c l i t o r o m e g a l y and i r r e g u l a r menses. The f a t h e r ( P t 5 ) was 170 cm t a l l and a p p a r e n t l y normal. Basal (B) and Cortrosyn@ s t i m u l a t e d (S) serum a d r e n a l s t e r o i d s a r e l i s t e d below. P t 17-OHP ) DR1 The f i n d i n g s i n t h i s f a m i l y i l l u s t r a t e t h e spectrum of LOCAH r a n g i n g from no symptoms ( P t s 3 , 5 ) , t o r a p i d growth ( P t s 1 , 2 ) , p r emature pubarche and c l i t o r o m e g a l y ( P t l ) , and p o s t p u b e r t a l h i r s ut i s m and oligomenorrhea ( P t 4 ) . There a p p e a r s t o be no c o r r e l a t i o n between t h e biochemical a b n o r m a l i t i e s and t h e c l i n i c a l m a n i f e s t at i o n s of t h e d i s e a s e .
HYPOPITUITARISM AND PRECOCIOUS PUBERTY ( P P ) . G. C o s t i n and F. Kaufman. Univ. of So. Cal. Sch. o f Med., Dept.
421 of Peds., C h i l d r e n s Hosp. o f Los Angeles, Los Angeles.
T h r e e g i r l s and o n e boy w i t h h y p o p i t u i t a r i s m owing t o h i s t i o c yt o s i s ( # 2 , 3 ) and t o c r a n i a l r a d i a t i o n f o r a craniopharyngioma ( # I ) and a t h a l a m i c tumor ( # 4 ) developed PP. S i g n s of s e x u a l p r e c o c i t y were n o t e d p r i o r t o t r e a t m e n t w i t h s o m a t o t r o p i n (HGH) i n 3 pat i e n t s , and d u r i n g t h e c o u r s e of t h e r a p y i n one. C l i n i c a l and l a bo r a t o r v d a t a a r e i n d i c a t e d below. 3.5 0.9 5.2 1 2 100 While i n p a t i e n t #2 t h e r e was a normal growth v e l o c i t y a s s o c i a t e d w i t h p u b e r t y , i n p a t i e n t #3 t h e growth s p u r t was subnorma1;in b o t h p a t i e n t s menses s t a r t e d a t 11-114 y r s . F i v e y r s a f t e r t h e o n s e t of PP t h e CA/HA/BA r a t i o s i n p a t i e n t s #2 and 3 were 1 2 f / l l f / 1 4 and 1 3 f / l O f / 1 5 , r e s p e c t i v e l y . I n t h e o t h e r 2 p a t i e n t s , t h e CA/HA/BA r at i o s I f y r s a f t e r o n s e t of PP were 8 f / 7 4 / 7 4 ( # 1 ) and 1 0 / 5 f / 1 0 ( # 4 ) . These f i n d i n g s i n d i c a t e t h a t 1 ) s e x u a l p r e c o c i t y does o c c u r i n t h e p r e s e n c e of h y p o p i t u i t a r i s m , 2) t h e r e is a r a p i d s k e l e t a l matu r a t i o n b e f o r e c l i n i c a l s i g n s of PP a r e a p p a r e n t , and 3) t h e pub e r t a l growth s p u r t even i f a d e q u a t e does n o t r e s u l t i n a normal a d u l t h e i g h t i f t h e r e is an abnormal HA/BA r a t i o a t t h e o n s e t of PP. We submit t h a t i n t h e s e p a t i e n t s f o r achievement of an a v e r a g e h e i g h t PP must be c u r t a i l e d by pharmacologic means u n t i l t h e HA/BA r a t i o i s normalized by t r e a t m e n t w i t h HGH. The 3' ends of the DScDNA were extended with deoxycytosine using terminal deoxynucleotidyl transferase; this "tailed" DScDNA was inserted into the Pst I site of pBR322 similarly tailed with deoxyguanosine. Transfomtion of E. coli 294 yielded >60,000 clones. Based on a partial porcine -aid sequence, we used the manual phosphoramidite method to synthesize a family of 32 15-base oligonucleotides and used these to prim the synthesis of a specific cDNA probe. Clones hybridizing to the 15mer-primxl cDNA were then probed with a different family of 64 17-base oligonucleotides we synthesized based on a different portion of the amino acid sequence. Of 10,000 clones containing cDNA inserts longer than 800 bases, 5 hybridize efficiently with both probes, indicating they carry bovine P450 cDNA sequences. These DNA clones w~l l permit the detem&iEion of the structure of bovine P450C21 as well as h m P450C21 and its pathogenic variants. 
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F e t a l p a n c r e a t i c t i s s u e (FPT) h a s a g r e a t p o t e n t i a l f o r p r o l if e r a t i o n and may p r o v i d e a s u i t a b l e s o u r c e f o r t r a n s p l a n t a t i o n i n t r e a t i n g d i a b e t e s m e l l i t u s . I n o r d e r t o c h a r a c t e r i z e i t s i n su l i n producing c a p a c i t y , 8
human f e t a l p a n c r e a s e s o f 13-20 wk. g e s t . were s t u d i e d i n organ c u l t u r e f o r 7 days. DNA and i n s u l i n c o n t e n t and r e l e a s e i n t o t h e culture-medium from day 3 t o 7 were measured. Two t y p e s of medium b o t h supplemented w i t h 20% (W/V) h e a t e d f e t a l c a l f serum were used: 1) E a g l e ' s minimum essential medium (MEM) was supplemented w i t h 6 t i m e s t h e b a s a l c o n c e n t r a ti o n of E M c o n t a i n i n g 5 (7EAAlG) o r 16.5 (7EAA3G) mmol/l g l u c o s e and 2) "RPMI 1640 medium" c o n t a i n e d 11.6 (R) o r 23.2 (RG) mmol/l g l u c o s e . Glucose enrichment i n c r e a s e d t i s s u e i n s u l i n c o n t e n t (iiU l u g DNA) by 44 t o 263% i n 7EAA (20.511.5 i n 1G v s 3 8 . 9 5 . 6 i n 3G;p. 0.01) and by 34 t o 276% i n RPMI (16.9t1.5 i n R v s 36.252.9 i n RG;p0.01). High E M c o n c e n t r a t i o n i t s e l f favoured t i s s u e i ns u l i n s y n t h e s i s (7EAAlG l a r g e r t h a n R;p: 0.001 and RG 3 1 . 1 5 . 7 v s R 12.1k2.6 uU/ug DNA;p: 0.001). The i n s u l i n s p e c i f i c a c t i v i t y (uU I / u g DNA) o f FPT i n c r e a s e d w i t h g e s t . age being 0.24 a t wk. 13 and 1.62 a t wk. 20 i n t h e f r e s h t i s s u e and a f t e r 7 days o f c u l cu r e 25.2 a t wk. 13 and 61.3 a t wk. 2 0 . R e s u l t s indicate: 1) both i n s u l i n s y n t h e s i s and r e l e a s e of FPT and HFPC i n c r e a s e d i n respo n s e t o g l u c o s e and e s s e n t i a l amino a c i d s and 2) t h e combination of h i g h g l u c o s e and h i g h e s s e n t i a l amino a c i d s c o n t a i n i n g medium can p o t e n t i a t e t h e f e t a l p a n c r e a t i c t i s s u e c a p a c i c y f o r i n s u l i n s y n t h e s i s i n a t r a n s p l a n t .
GROWTH HORMONE RELEASE FOLLOWING ADMINISTRATION OF GROWTH HORMONE RELEASING FACTOR TO GROWTH HORMONE
424 DEFICIENT AND NORMAL MALES. Floyd L . C u l l e r and Kenneth Lee J o n e s , UCSD School of Medicine, Dept. of P e d i a t r i c s , La J o l l a , C a l i f o r n i a .
W e have s t u d i e d 4 males w i t h i d i o p a t h i c growth hormone (hGH) d e f i c i e n c y and 8 normal a d u l t males comparing t h e i r r e s p o n s e s t o a 100 ug b o l u s i n f u s i o n o f t h e 44 amino a c i d s y n t h e t i c growth hormone r e l e a s i n g f a c t o r (GRF-44). Responses were compared f o r changes i n h a , p r o l a c t i n (PRL), in.sulin ( I ) , glucagon (G) and g l u c o s e (Glu) c o n c e n t r a t i o n o v e r a 2-hour p e r i o d a f t e r i n j e c t i o n of GRF-44. hGH d e f i c i e n c y was i n i t i a l l y documented u s i n g s t a n da r d t e s t i n g p r o c e d u r e s . No p a t i e n t had r e c e i v e d hGH replacement f o r a t l e a s t one month p r i o r t o t e s t i n g .
The hGH d e f i c i e n t p a t i e n t s had a s i g n i f i c a n t (pcO.05) GRFinduced i n c r e a s e i n hGH c o n c e n t r a t i o n from a b a s e l i n e o f 2.7f0.7 ng/ml (MfSEM) t o a peak of 10.3k3.2 nglml . The normal males showed a much g r e a t e r (p<0.005) change i n hGH l e v e l s w i t h a peak r e s p o n s e of 4 6 . 0 5 . 8 nglml from a b a s e l i n e o f 2.98+0.1 nglml, There were no changes i n PRL, Glu, I o r G i n e i t h e r group.
W e have demonstrated t h a t p a t i e n t s with subnormal hGH responses t o t r a d i t i o n a l s t i m u l i c a n g e n e r a t e hGH l e v e l s i n t h e normal range ( > 7 ng/ml) f o l l o w i n g GRF s t i m u l a t i o n .
The mean i n c r e a s e of t h e hCH d e f i c i e n t group, however, was o n l y 22% of t h e mcan i nc r e a s e o f t h e proup o f normal male c o n t r o l s . 
TREATMENT AT 3 YEARS OF AGE. T-i>J-_D-aa~-,->-e_"_"i~_S
425 pPa_n_emann F'a-ud&J>&i_sh, R~bert~~.-E_h~rlJ~c_h_, Univers i t y of Toronto, Hosp. f o r S i c k C h i l d r e n , Toronto, Canada. 69 c h i l d r e n were d e t e c t e d by a low t h y r o x i n e (T4) a n d / o r e l e v a t e d t h y r o t r o p i n (TSH) on n e o n a t a l s c r e e n i n g t o have cong e n i t a l hypothyroidism (CH). Of t h e s e , 55 a r e 3 y e a r s o f age o r o l d e r .
Thyroid s c a n n i n g a t d i a g n o s i s showed 16/55 were a t h y r o t i c (A), 21/55 had g o i t e r s (G) and 1 8 w i t h e c t o p i c (E) g l a n d s . E were excluded because of t h e anatomic a b n o r m a l i t y . 22 of t h e remaining 37 showed a secondary r i s e of TSH t o > 1 0 mU/L c o n f i r m i n g t h e d i a g n o s i s d u r i n g t h e f i r s t 3 y e a r s . I n 15 w i t h continuous TSH s u p p r e s s i o n , t h y r o x i n e was d i s c o n t i n u e d a t age 3 y e a r s o r more.
I n t h e f i r s t 6 , TSH was measured a t 6 weeks: i n 516 i t was > 6 0 , i n 1 w i t h G-CH, TSH was 7 a t 6 weeks and 1 5 a t 8 weeks.
Symptoms of hypothyroidism o c c u r r e d i n 416. TSH was t h e n measured a t 3 weeks and was > 6 0 i n t h e remaining 10. When t h e TSH was e l e v a t e d , T4 was 40+39 nmol/L (X+SD). I n a l l p a t i e n t s w i t h A-CH o r G-CH, t h e d i a g n o s i s was confirmed e i t h e r by a secondary r i s e o f TSH while on t r e a t m e n t o r by a TSH r i s e a t 3-6 weeks a f t e r d i s c o n t i n u i n g t h e r a p y .
I n t h i s group, t h y r o i d s c r e e n i n g a p p e a r s t o be 100% s p e c i f i c . Hypot h a l a m i c -p i t u i t a r y r e s p o n s i v e n e s s and hypothyroid symptoms r e t u r n very r a p i d l y a f t e r s t o p p i n g L-T4 t h e r a p y . W e recommend TSH measurement 3 weeks a f t e r s t o p p i n g L-T4 i n c h i l d r e n with CH > 3 y e a r s i n whom c o n f i r m a t i o n o f t h e i n i t i a l d i a g n o s i s i s d e s i r a b l e .
